Aurobindo Pharma share news, announcements and annual reports
NSE: AUROPHARMABSE: 524804Pharmaceuticals & BiotechnologyMid Cap
Aurobindo Pharma Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 1995 on BSE, Jul 2000 on NSE
Last close ₹1,681.40up ₹21.50 (1.30%)BSE ₹1,677.80
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,659.90.
30 Oct: open ₹1,652.00, high ₹1,687.00, low ₹1,647.20
52-week range of traded prices to 30 Oct 2026
₹1,091.20Low, 30 Oct 2025₹1,740.00High, 24 Sep 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results and dividend. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹96,744 Cr138th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 26.06
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.55
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 10.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 11.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.20
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 9,52,65057.5% delivered
Aurobindo Pharma share news and announcements
1,689 announcements, routine notices left out, newest first. Page 22 of 34.
Oct 2015
Sep 2015
Aug 2015
28 Aug · Disclosure of Voting Pattern - Clause 35A
17 Aug · Corporate action
Aurobindo Pharma Limited had informed the Exchange that the Register of Members and Share Transfer Books of the Company will be closed from August 25, 2015 to August 27, 2015 (both days inclusive) for the purpose of Annual General Meeting. The Company has now informed the Exchange that aforesaid book closure dates will also be considered to determine the entitlement of the shareholders to the interim dividend of 50% i.e. Re.0.50 (Paise fifty only) per equity share of Re .1/- each on the equity share capital of the Company for the year 2015-16 as approved by the Board on August 12, 2015.(Purpose Revised)
Jul 2015
22 Jul · News Verification
Exchange has sought clarification from Aurobindo Pharma Limited with respect to recent news item captioned Aurobindo Pharma Comes Under US FDA Lens over Quality Management ". The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Aurobindo Pharma Limited vide its letter inter alia stated that "The said facility underwent a routine GMP inspection BY USFDA and there are certain observations related to the systems and procedures. The company is appropriately responding and this has no perceived impact on the operations and exports from the said facility" .22 Jul · News Verification
Exchange has sought clarification from Aurobindo Pharma Limited, with respect to recent news item captioned "Aurobindo Pharma Comes Under US FDA Lens over Quality Management ". In this regard, the Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such negotiations were taking place and b) Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading. The response from the Company is awaited.10 Jul · Disclosure of Voting Pattern - Clause 35A
Jun 2015
May 2015
28 May · Meeting
Annual General Meeting of the Company will be held on August 27, 2015. Further the Register of Members and Share Transfer Books of the Company will be closed from August 25, 2015 to August 27, 2015 (both days inclusive) for the purpose of Annual General Meeting .28 May · Dividend
Interim Dividend will be paid on or before June 23, 2015.28 May · Corporate action
Company has fixed Record Date as June 9, 2015 for the purpose of Third Interim dividend for the year 2014-15.28 May · Corporate action
Board of Directors of the Company at its meeting held on May 28, 2015, inter alia, has considered and recommended for issue of ONE bonus equity share for every ONE equity share held as on a Record Date to be determined. The Bonus Issue will be subject to the approval of the shareholders at the Extraordinary General Meeting of the Company to be held on July 09, 2015 and other applicable statutory and regulatory approvals, if any.
Apr 2015